BRIEF published on 11/18/2024 at 18:15, 2 days 19 hours ago Freelance.com: 3rd Quarter Revenue Growth Revenue Growth International Expansion Strategic Acquisitions Freelance.com 3rd Quarter 2024
PRESS RELEASE published on 11/18/2024 at 18:10, 2 days 19 hours ago Freelance.com: 3rd quarter revenues Freelance.com reports €242.6m revenues in 3rd quarter 2024, showing 22% YoY growth. Year-to-date revenue as of 30 Sept 2024: €759.7m (+23%). Positive organic growth in France and internationally Revenues Organic Growth Freelance.com 3rd Quarter International Activities
BRIEF published on 10/21/2024 at 18:55, 30 days 19 hours ago Freelance.com: Review of the First Half of 2024 Financial Results Organic Growth Economic Outlook Turnover Freelance.com
PRESS RELEASE published on 10/21/2024 at 18:50, 30 days 19 hours ago Freelance.com: 1st semester 2024 results Freelance.com announces 1st semester 2024 results with €517.0 million revenue (+23%) and €16.3 million EBITDA (+13%). The European leader in talent solutions maintains proforma EBITDA margin amidst economic challenges Financial Results Revenue Growth EBITDA Margin Freelance.com 1st Semester 2024
BRIEF published on 10/07/2024 at 18:06, 1 month 13 days ago Freelance.com consolidates its position with the acquisition of the Prium group Acquisition Freelance.com Salary Portage Prium Economy Of Scale
BRIEF published on 09/20/2024 at 23:03, 2 months ago Freelance.com 2023 Universal Registration Document Available AMF TaaS Universal Registration Document Freelance.com Sourcing Expertise
BRIEF published on 08/26/2024 at 17:45, 2 months 25 days ago Freelance.com: 2nd Quarter 2024 Revenue Reaches €258.8m, Up 23% Revenue Growth Market Conditions International Expansion France Performance Future Events
PRESS RELEASE published on 08/26/2024 at 17:40, 2 months 25 days ago Freelance.com: 2nd quarter 2024 revenue: €258.8m (+23%) Freelance.com announces 2nd quarter 2024 revenue of €258.8m, a 23% increase year-on-year, reaching a total of €517.1m in the 1st semester of 2024. The company confirms slightly positive organic growth guidance for 2024 Revenue Organic Growth Freelance.com Guidance 2nd Quarter
BRIEF published on 07/30/2024 at 16:34, 3 months 21 days ago FREELANCE.COM: Half-year review of the H1 2024 liquidity contract Liquidity Contract Actions Half-yearly Report Gilbert Dupont Freelance.com
BRIEF published on 07/30/2024 at 16:32, 3 months 21 days ago Freelance.com: Half-yearly review of the H2-2023 Liquidity Contract Securities Liquidity Contract Freelance.com Half-yearly Review Gilbert Dupont Stock Exchange Company
Published on 11/21/2024 at 13:30, 36 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 36 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 30 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 51 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 8 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 46 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 21 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 21 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
